Upfront T-DXd Combo Nearly Doubles PFS in HER2-Positive Breast Cancer

By News Health
11 hours Ago

(MedPage Today) — At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic HER2-positive breast cancer. The combination…

Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsbreastca/116216

Author :

Publish date : 2025-06-24 15:23:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Enigmatic lizards somehow survived near Chicxulub asteroid impact

Millions of children at risk as vaccination uptake stalls

Physician Lawmaker Confronts RFK Jr. About ACIP Firings: 'You Lied'

Health Groups Cautiously Optimistic on Prior Authorization Announcement

Women's pelvises are shrinking – how is that changing childbirth?

Blood-Based KRAS Testing Fails in Ovarian Cancer